Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.

Journal of medicinal chemistry - 28 Dec 2017

Xie Jingjing, Si Xiaojia, Gu Shoulai, Wang Mingliang, Shen Jian, Li Haoyan, Shen Jian, Li Dan, Fang Yanjia, Liu Cong, Zhu Jidong

Abstract excerpt

SHP2, a cytoplasmic protein-tyrosine phosphatase encoded by the PTPN11 gene, is involved in multiple cell signaling processes including Ras/MAPK and Hippo/YAP pathways. SHP2 has been shown to contribute to the progression of a number of cancer types including leukemia, gastric, and breast cancers. It also regulates T-cell activation by interacting with inhibitory immune checkpoint receptors such as the programmed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Allosteric Regulation
Share to Drug Screening Assays, Antitumor

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Inhibitory Concentration 50

Share to Naphthalenes

Share to Piperidines

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Thiazoles

Share to YAP-Signaling Proteins

Source

Identifiers

PMID: 29155585
DOI: 10.1021/acs.jmedchem.7b01520

Genes

BTLA
PTPN11

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.PMID 29155585Read ↗

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.Semantic proximity Read ↗

Strategies to overcome drug resistance using SHP2 inhibitorsSemantic proximity Read ↗

Allosteric Inhibitors of SHP2: An Updated Patent Review (2015-2020).Semantic proximity Read ↗

Inhibition of SHP2 as an approach to block RAS-driven cancers.Semantic proximity Read ↗

Targeting SHP2 phosphatase in hematological malignancies.Semantic proximity Read ↗

The Landscape of Protein Tyrosine Phosphatase (Shp2) and CancerSemantic proximity Read ↗

Therapeutic potential of targeting SHP2 in human developmental disorders and cancers.Semantic proximity Read ↗

Consideration of SHP-1 as a Molecular Target for Tumor TherapySemantic proximity Read ↗

Exploring the mechanism of the potent allosteric inhibitor compound2 on SHP2 WT and SHP2F285S by molecular dynamics study.Semantic proximity Read ↗

Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.Semantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting Its Protein-Protein Interactions.Semantic proximity Read ↗

Targeting Oncogenic Src Homology 2 Domain-Containing Phosphatase 2 (SHP2) by Inhibiting its Protein-Protein InteractionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.